AB Science (AB.PA) Announces That FDA Authorization (IND) Has Been Granted for the Initiation of Its Phase 3 Study in Severe Asthma. Patient Recruitment Commences in the US
9/14/2011 10:15:00 AM
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has obtained IND status (Investigation New Drug – authorization to administer an investigational drug to humans) from the US Food and Drug Administration (FDA) and can now commence its phase 3 study of masitinib in severe persistent asthma in the US. This study had previously received European authorization and has therefore already commenced patient recruitment from European sites earlier this year.
comments powered by